Cosmo Pharmaceuticals NV (XSWX:COPN) ROCE % : 31.76% (As of Jun. 2024)

View and export this data going back to 2007. Start your Free Trial

What is Cosmo Pharmaceuticals NV ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Cosmo Pharmaceuticals NV's annualized ROCE % for the quarter that ended in Jun. 2024 was 31.76%.

Cosmo Pharmaceuticals NV ROCE % Historical Data

The historical data trend for Cosmo Pharmaceuticals NV's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cosmo Pharmaceuticals NV ROCE % Chart

Cosmo Pharmaceuticals NV Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-2.13

0.31

4.78

4.83

1.80

Cosmo Pharmaceuticals NV Semi-Annual Data
	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
ROCE %	Get a 7-Day Free Trial															3.56	5.98	2.96	0.68	31.76

Cosmo Pharmaceuticals NV ROCE % Calculation

Cosmo Pharmaceuticals NV's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	9.485	/	( ( (749.614 - 192.385)	+	(522.445 - 24.25) )	/ 2 )
	=	9.485	/	( (557.229	+	498.195)	/ 2 )
	=	9.485	/	527.712
	=	1.80 %

Cosmo Pharmaceuticals NV's ROCE % of for the quarter that ended in Jun. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Jun. 2024 )		(Q: Dec. 2023 )		(Q: Jun. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Jun. 2024 )		(Q: Dec. 2023 )		(Q: Jun. 2024 )
	=	170.82	/	( ( (522.445 - 24.25)	+	(614.069 - 36.443) )	/ 2 )
	=	170.82	/	( ( 498.195	+	577.626 )	/ 2 )
	=	170.82	/	537.9105
	=	31.76 %

(1) Note: The EBIT data used here is two times the semi-annual (Jun. 2024) EBIT data.

Cosmo Pharmaceuticals NV (XSWX:COPN) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Cosmo Pharmaceuticals NV ROCE % Related Terms

Thank you for viewing the detailed overview of Cosmo Pharmaceuticals NV's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Cosmo Pharmaceuticals NV Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cosmo Pharmaceuticals NV (XSWX:COPN) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

COPNz:UK 0RGI:UK C43:Germany

Address

Sir John Rogerson’s Quay, Riverside II, Dublin, IRL, 2

Website

https://www.cosmopharma.com

Cosmo Pharmaceuticals NV is a pharmaceutical company with a focus on gastrointestinal diseases, dermatology and healthtech. The company develops and manufactures products that are distributed globally by its partners. Products that the company has developed include Lialda/Mezavant/Mesavancol and Uceris/Cortiment, for the treatment of ulcerative colitis; GI Genius, which uses artificial intelligence to aid the detection of colorectal polyps during colonoscopy; Eleview, a submucosal injectable composition for use in gastrointestinal endoscopic procedures; Aemcolo for the treatment of travellers' diarrhoea (TD) and Winlevi for the treatment of acne. Product pipeline includes Breezula, GI Genius, Methylene blue MMX, Aemcolo, CB-03-10 and CB-01-33.

Cosmo Pharmaceuticals NV Headlines

No Headlines